Compare NRG Energy Inc (NRG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NRG Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? NRG Energy Inc trades at $108.2 (market cap $22.35B), while Vertex Pharmaceuticals Incorporated trades at $503.25 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 5.7× NRG Energy Inc's market cap, and NRG Energy Inc pays a 1.79% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold NRG Energy Inc for 62 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| NRG | VRTX | |
|---|---|---|
Market Cap | $22.35B | $127.55B |
Volume | 5,011,942 | 1,487,944 |
Sector | Utilities | Health |
52-Week High | $184.03 | $557.96 |
52-Week Low | $95.23 | $407.37 |
Typical Hold Time | 62 Days | 120 Days |
Enterprise Value | $46.30B | $121.68B |
Dividend Yield | 1.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $108.61, up 4.84% with bullish technical signals and strong analyst support. The stock shows robust fundamentals with $30.71B revenue, 2.56% net margin, and attractive valuation at P/E 28.28 and P/S 0.66. Recent developments include a transformative 1.2 GW Texas data center power project and LS Power acquisition driving growth. Cash flow trends improved significantly from 2023's negative $1.5B to 2025's positive $3.83B, though 2026 projects a temporary dip.
Outlook remains positive with 70% analyst buy ratings and $202.90 consensus target representing 87% upside. Key opportunities include data center expansion and customer-backed power projects, while risks involve elevated debt levels (56.42% debt-to-asset ratio) and recent earnings misses. The stock presents growth potential but requires monitoring of execution on major capital projects.
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% on the day, with a bearish technical signal despite a neutral oscillator reading. The company reported strong 2025 revenue of $12.00B and net income of $3.95B, with a net margin of 35%. Recent positive Phase 2b data for its kidney disease drug inaxaplin highlights pipeline expansion beyond cystic fibrosis dominance. Analyst consensus is strongly bullish with an 83.9% buy rating and a $573.50 price target, implying 13.4% upside.
The outlook for VRTX is positive, driven by its profitable core business and promising pipeline, but faces risks from clinical trial outcomes and competitive pressures. The stock's current valuation at a P/E of 29.45 is reasonable given its growth prospects, though investors should monitor execution on new drug approvals and market adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
